HKAM
CRSP icon

Horizon Kinetics Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Horizon Kinetics Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$510K Sell
9,353
-443
-5% -$23.4K 0.01% 212
2026
Q1 		$466K Sell
9,796
-443
-4% -$23.4K 0.01% 228
2025
Q4 		$537K Sell
10,239
-443
-4% -$26.5K 0.01% 217
2025
Q3 		$692K Buy
10,682
+443
+4% +$25.4K 0.01% 200
2025
Q2 		$498K Sell
10,239
-443
-4% -$17.1K 0.01% 242
2025
Q1 		$364K Hold
10,682
– – ﹤0.01% 259
2024
Q4 		$420K Buy
10,682
+443
+4% +$20.9K 0.01% 251
2024
Q3 		$481K Sell
10,239
-443
-4% -$22.5K 0.01% 237
2024
Q2 		$577K Hold
10,682
– – 0.01% 206
2024
Q1 		$728K Hold
10,682
– – 0.01% 186
2023
Q4 		$669K Sell
10,682
-443
-4% -$24.5K 0.01% 190
2023
Q3 		$505K Hold
11,125
– – 0.01% 212
2023
Q2 		$625K Hold
11,125
– – 0.01% 199
2023
Q1 		$503K Buy
11,125
+5,000
+82% +$243K 0.01% 213
2022
Q4 		$249K Hold
6,125
– – ﹤0.01% 266
2022
Q3 		$400K Hold
6,125
– – 0.01% 231
2022
Q2 		$372K Hold
6,125
– – 0.01% 246
2022
Q1 		$384K Hold
6,125
– – 0.01% 263
2021
Q4 		$464K Hold
6,125
– – 0.01% 249
2021
Q3 		$686K Hold
6,125
– – 0.02% 214
2021
Q2 		$992K Hold
6,125
– – 0.02% 179
2021
Q1 		$746K Hold
6,125
– – 0.02% 209
2020
Q4 		$938K Hold
6,125
– – 0.03% 186
2020
Q3 		$512K Hold
6,125
– – 0.02% 242
2020
Q2 		$450K Buy
6,125
+1,000
+20% +$58.5K 0.02% 250
2020
Q1 		$217K Buy
+5,125
New +$265K 0.01% 308

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Horizon Kinetics Asset Management's CRSP Position: Q2 2026 in Review

Horizon Kinetics Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 4.5% in Q2 2026, selling an estimated $23.4K and leaving 9,353 shares worth $510K. The position accounts for 0.01% of the portfolio, ranked #212.

Horizon Kinetics Asset Management first reported a position in CRSP in Q1 2020 and has held it in 26 quarters since. The position peaked at $992K in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Horizon Kinetics Asset Management held 9,353 shares of CRISPR Therapeutics worth $510K as of Q2 2026.
  • Horizon Kinetics Asset Management sold 443 CRISPR Therapeutics shares in Q2 2026, an estimated $23.4K.
  • CRISPR Therapeutics made up 0.01% of Horizon Kinetics Asset Management's portfolio in Q2 2026, its #212 holding.
  • Horizon Kinetics Asset Management first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Horizon Kinetics Asset Management's CRISPR Therapeutics position peaked at $992K in Q2 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.